The chromosomal region 13q14.3 is frequently deleted in B cell chronic lymphocytic leukemia (B-CLL) and it is supposed that a tumor suppressor gene, involved in this leukemogenesis, is located in this area. The first exons of two genes, Leu1 and Leu2, mapped in a minimally deleted 13q14.3 region, are systematically lost in B-CLL sharing a 13q14.3 deletion. These two genes have been proposed as strong tumor suppressor gene candidates. However, in a study on 15 13q14.3 deleted B-CLL, we found three patients in which this critical region was not involved. Because of these results and that no mutations were detected on the two genes in a previous study, we think that Leu1 and Leu2 can be excluded as tumor suppressor genes.
Introduction
Since it accounts for 30% of all leukemia in adults, B cell chronic lymphocytic leukemia (B-CLL) is the most common hemopathy among Europeans. The two major cytogenetic features observed in B-CLL are chromosome 12 trisomy and chromosome 13 deletions. [1] [2] [3] A locus in 13q14.3 ( Figure 1a ), telomeric to RB and containing genetic markers D13S25 and D13S319, is very frequently involved in the deletions observed on chromosome 13. [4] [5] [6] [7] [8] [9] It has been supposed that a tumor suppressor gene, other than RB, 10 named DBM (disrupted in B cell malignancies) is located in this region. 4 Several teams have cloned different but overlapping critical deleted regions. [11] [12] [13] [14] Transcription maps of these regions are under construction. [14] [15] [16] Two candidate genes, located just centromeric to D13S319 (Figure 1a) , called Leu1 and Leu2 have been proposed as tumor suppressor genes involved in B-CLL since the first exon of any of these two genes was deleted in all cases of 13q14.3 loss examined.
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Materials and methods
PCR analysis
Fifteen B-CLL samples have been tested for Leu1 and Leu2 deletions. All of them have shown loss of heterozygosity (LOH) at 13q14.3 in previous studies 8, 12 based on microsatellites analysis. We performed four PCR experiments investigating the Leu1 and Leu2 locus with the primers described by Liu et al: 15 Leu1 exon 1 (primers C12T7(3)-F, C12T7(4)-R; primers C12T7(5)-F; C12T7(6)-R), Leu2 exon 1 (primers C12 Notl(6)-R; Internal (3)-F); and the region between Leu1 and Leu2 (primers Internal (1)-F; Internal (2)-R).
A control PCR product, corresponding to a constant region of the immunoglobulin heavy chain locus, 17 which is not normally deleted in B-CLL, was used under the same conditions (3ЈS: primers TCTACACTGCGTTCCCCATCAC and CGTTCT GAGTGCCCTCACTACTTG). This was included in the same reaction tubes, for each PCR as a reference for normalizing measurement differences due to variations in the quantity of the analyzed sample DNA. We performed 25 PCR cycles on 10 ng of each sample DNA.
LOH evaluation
Allelic loss was evaluated by quantifying, with a PhosphoImager scanner (Molecular Dynamics, Sunnyvale, CA, USA) the radioactive emission of the PCR products, after hybridization with the corresponding radiolabeled probe. For each patient, we investigated their normal blood cells for control DNA reference, and leukemic cells. We calculated the ratio of the 'signal of chromosome 13 PCR' vs 'signal of the control PCR' for these two types of cells. When the ratio of leukemic cells was lower than 70% for normal cells, we diagnosed a heterozygous deletion. When this ratio was under 30%, we diagnosed a double deletion. Each result has been validated by three sets of experiments (PCR and quantification).
Results and discussion
The deletion pattern of sample number 63 has been precisely defined in a previous study, 12 with a deletion area telomeric to marker AFM206XF12 and extending over marker D13S294. Therefore, sample number 63 shares a deletion involving a region about 200 kb telomeric to Leu1 and Leu2 locus (see Figure 1b) , and is not deleted for any of these two genes. This result has been confirmed by quantification at the Leu1 and Leu2 locus and the results of the PCR amplification are shown in Figure 2 .
The second sample number 65, is deleted with respect to marker D13S25, but not deleted with the proximal marker GCT16C05, and presents a deletion of marker AFM206XF12. Markers D13S272 or D13S319 are not informative (Figure 1b) , but the allelic dosage at the Leu1 and Leu2 locus confirms that the two alleles are retained, again excluding these two genes.
The third sample number 67, is only deleted at marker D13S25, and is not informative for markers between 206XF12 and D13S25. However, this sample shares no deletion for the Leu1 and Leu2 locus or for markers D13S319, D13S272 and 206XF12, again excluding the Leu1 and Leu2 locus.
Our results of these three different cases clearly demonstrate that the claim that Leu1 and Leu2 are systematically deleted in all B-CLL sharing a 13q14.3 deletion cannot be retained. Furthermore, our data confirms our previous description 12 of a more telomeric minimal deleted critical region. However, the Leu1 and Leu2 locus is very frequently involved as shown in the first study performed by Liu et al, 15 and in the present study where 12 out of 15 samples are heterozygously deleted. Potential significance of this discrepancy, correlated to the fact that deletions are usually larger than the Leu1 and Leu2 locus and not clustered in a single critical region, could be discussed.
Firstly, one of these two genes is actually the DBM gene, but the characterized transcripts of 1.1 kb and 1.8 kb for Leu1 and Leu2 mRNAs respectively correspond to alternative spliced mRNAs. It is possible that a larger transcript may be found at some stage of the B cell maturation and extends to a more telomeric region, corresponding to the minimally deleted region that we have characterized in the three patients of our study. Therefore, alterations or mutations of the Leu1 or Leu2 genes should reside in these alternative spliced exons. This hypothesis may explain that Liu et al did not find any mutations in Leu1 or Leu2 genes in heterozygous deleted patients. Therefore the Leu1 or Leu2 genes cannot be the candidate genes as has been previously put forward.
A second hypothesis is that the DBM gene is a very large gene. According to the different minimal core regions defined by several teams, [4] [5] [6] [7] [8] [9] 12 the gene could extend from marker D13S273 to marker D13S294, for example on a genomic stretch of one megabase. In this situation, Leu1 and Leu2 may be genes located in the intron of the DBM gene. This intron's frequent involvement in deletions, possibly due to a highly unstable genomic region, can alter the transcription rate of the DBM gene.
Finally, it cannot be excluded that some deletions do not involve the DBM gene itself but affect its expression by deleting regulating sequences.
